{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:31:58Z","timestamp":1793255518902,"version":"4.5.0"},"reference-count":46,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Opioid use disorder (OUD) leads to significant morbidity and mortality. While opioid agonist therapies like transmucosal buprenorphine and methadone are effective, they face challenges such as poor adherence, diversion risk and suboptimal abstinence rates, prompting the development of long-acting injectable (LAI) buprenorphine. However, comparative evidence among LAIs and versus standard treatments remains limited. The aim of this study is to provide comparative evidence among buprenorphine LAIs and versus oral opioid agonist treatments.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We conducted a systematic literature review and network meta-analysis (NMA) evaluating the effectiveness and safety of LAI buprenorphine treatments (extended-release buprenorphine [BUP-XR; monthly injection] and other BUP-LAI [weekly and monthly injection]) versus transmucosal buprenorphine, methadone and buprenorphine implants in adults with OUD. The review included randomized controlled trials (RCTs) and non-RCTs for LAIs (January 2012 and March 2025). Primary outcomes were treatment discontinuation and illicit opioid use. Secondary outcomes were safety and health-related quality of life. Data were synthesized using univariate NMAs, bivariate NMA with surrogate end point modelling. Studies with limited data and single-arm designs were incorporated by using study-level matching techniques.\n                    <jats:bold>Results:<\/jats:bold>\n                    Ninety-eight studies met the inclusion criteria. BUP-XR demonstrated the highest probability of achieving treatment retention and opioid abstinence across analyses. In combined evidence (RCTs and non-RCTs), BUP-XR showed significantly lower risk of illicit opioid use versus transmucosal buprenorphine (rate ratio [RR] 1.99; 95% credible interval [CrI]: 1.29\u20133.11) and methadone (RR: 2.66; 95% CrI: 1.40\u20133.56). BUP-XR showed borderline significantly lower risk of illicit opioid use versus other BUP-LAI (RR: 1.81; 95% CrI: 0.97\u20133.55) and buprenorphine implant (RR: 2.28; 95% CrI: 0.98\u20135.38). Treatment discontinuation rates were similar between OUD treatments. Safety outcomes were generally comparable across treatments. Health-related quality of life indicated better recovery among patients treated with BUP-XR.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    BUP-XR may enhance treatment retention and abstinence over other OUD therapies, supporting its integration into clinical pathways. The results may help guide future updates to OUD treatment guidelines and policies aimed at optimizing the use of long-acting formulations. Additional research is needed to better define the comparative effectiveness of LAIs.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0171","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:17:23Z","timestamp":1768209443000},"source":"Crossref","is-referenced-by-count":8,"title":["Effectiveness and safety of therapies for patients with opioid use disorder: a systematic review and network meta-analysis"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-9892","authenticated-orcid":false,"given":"Madhusudan","family":"Kabra","sequence":"first","affiliation":[{"name":"Indivior Ltd, Slough, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Srivastava","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Gautam","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janharpreet","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Oksanen","sequence":"additional","affiliation":[{"name":"Kotkan Korvaushoitoyksikk\u00f6 (Kotka OST Clinic), Kotka, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Griffith University, Brisbane, Queensland, Australia"},{"name":"Currumbin Clinic, Currumbin, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lee","sequence":"additional","affiliation":[{"name":"London RAAM Clinic, London, ON N6A 1J3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Boyett","sequence":"additional","affiliation":[{"name":"North Mississippi Medical Center of Tupelo, MS 38801, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Santoro","sequence":"additional","affiliation":[{"name":"Section of Addiction Medicine, Tower Health System, Reading, PA 19605, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Gupta","sequence":"additional","affiliation":[{"name":"ConnectHEOR, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne De","family":"Jong-Laird","sequence":"additional","affiliation":[{"name":"Employee of Indivior Ltd, Slough, UK when study was conducted"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Ren","sequence":"additional","affiliation":[{"name":"ConnectHEOR Ltd, London, UK"},{"name":"School of Medicine &amp; Population Health, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th Edition. American Psychiatric Publishing, VA, USA (2013).","edition":"5"},{"key":"e_1_3_8_4_2","unstructured":"American Psychiatric Association. Opioid use disorder (2018). (Accessed: 20 March 2025). Available from: https:\/\/www.psychiatry.org\/patients-families\/addiction\/opioid-use-disorder\/opioid-use-disorder"},{"key":"e_1_3_8_5_2","unstructured":"Canadian Institute of Health Research Canadian Research Initiative on Substance Misuse (CRISM) National Guideline Review Committee. CRISM National Guideline for the clinical management of opioid use disorder (2018). (Accessed: 20 March 2025). Available from: https:\/\/crism.ca\/wp-content\/uploads\/2018\/03\/CRISM_NationalGuideline_OUD-ENG.pdf"},{"key":"e_1_3_8_6_2","unstructured":"American Society of Addiction Medicine (ASAM). The ASAM National Practice Guideline for the treatment of opioid use disorder 2020 focused update (2020). (Accessed: 20 March 2025). Available from: https:\/\/www.asam.org\/quality-care\/clinical-guidelines\/national-practice-guideline"},{"issue":"01","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1097\/QAI.0000000000000659","article-title":"HIV, HCV and health-related harms among women who inject drugs: implications for prevention and treatment","volume":"69","author":"Iversen J","year":"2015","unstructured":"Iversen J, Page K, Madden A, Maher L. HIV, HCV and health-related harms among women who inject drugs: implications for prevention and treatment. J. Acquir. Immune Defic. Syndr. 69(01), S176\u2013S181 (2015).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"6","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.amjms.2016.10.002","article-title":"Endocarditis as a marker for new epidemics of injection drug use","volume":"352","author":"Keeshin SW","year":"2016","unstructured":"Keeshin SW, Feinberg J. Endocarditis as a marker for new epidemics of injection drug use. Am. J. Med. Sci. 352(6), 609\u2013614 (2016).","journal-title":"Am. J. Med. Sci."},{"issue":"1","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/appi.prcp.20180005","article-title":"Caring for patients with opioid use disorder: what clinicians should know about comorbid medical conditions","volume":"1","author":"Slawek DE","year":"2019","unstructured":"Slawek DE, Lu TY, Hayes B, Fox AD. Caring for patients with opioid use disorder: what clinicians should know about comorbid medical conditions. Psychiatr Res Clin Pract. 1(1), 16\u201326 (2019).","journal-title":"Psychiatr Res Clin Pract."},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.drugalcdep.2004.08.003","article-title":"Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies","volume":"76","author":"Wilcox HC","year":"2004","unstructured":"Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend. 76(Suppl.), S11\u2013S19 (2004).","journal-title":"Drug Alcohol Depend."},{"key":"e_1_3_8_11_2","volume-title":"Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (PEP24-07-021, NSDUH Series H-59)","author":"Substance Abuse and Mental Health Services Administration","year":"2024","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (PEP24-07-021, NSDUH Series H-59). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, MD, USA (2024). Available from: https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"e_1_3_8_12_2","unstructured":"World Health Organization. WHO updates guidelines on opioid dependence treatment and overdose prevention. (2025). Available from: https:\/\/www.who.int\/news\/item\/09-02-2025-who-updates-guidelines-on-opioid-dependence-treatment-and-overdose-prevention"},{"key":"e_1_3_8_13_2","volume-title":"State Unintentional Drug Overdose Reporting System (SUDORS) dashboard: fatal drug overdose data","author":"Centers for Disease Control and Prevention","year":"2025","unstructured":"Centers for Disease Control and Prevention. State Unintentional Drug Overdose Reporting System (SUDORS) dashboard: fatal drug overdose data. Department of Health and Human Services, Centers for Disease Control and Prevention, GA, USA (2025). https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html"},{"key":"e_1_3_8_14_2","unstructured":"Centre for Addiction and Mental Health (Canada). Opioid Agonist Therapy (2016). (Accessed: 20 March 2025). Available from: https:\/\/www.camh.ca\/-\/media\/files\/oat-info-for-clients.pdf"},{"issue":"4","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: detoxification and maintenance options","volume":"9","author":"Kleber HD","year":"2007","unstructured":"Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin. Neurosci. 9(4), 455\u2013470 (2007).","journal-title":"Dialogues Clin. Neurosci."},{"issue":"2","key":"e_1_3_8_16_2","first-page":"25","article-title":"The extent of misuse and diversion of medication for agonist opioid treatment: a review and expert opinions","volume":"17","author":"Alho H","year":"2015","unstructured":"Alho H, D'Agnone O, Krajci P The extent of misuse and diversion of medication for agonist opioid treatment: a review and expert opinions. Heroin Addict. Relat. Clin. Prob. 17(2\u20133), 25\u201334 (2015).","journal-title":"Heroin Addict. Relat. Clin. Prob."},{"issue":"5","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world","volume":"8","author":"Lofwall MR","year":"2014","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J. Addict. Med. 8(5), 315\u2013326 (2014).","journal-title":"J. Addict. Med."},{"key":"e_1_3_8_18_2","first-page":"117955731773732","article-title":"Perspectives on the pharmacological treatment of heroin addiction","volume":"8","author":"Bond AJ","year":"2017","unstructured":"Bond AJ, Witton J. Perspectives on the pharmacological treatment of heroin addiction. Clin. Med. Insights Psych. 8, 117955731773732 (2017).","journal-title":"Clin. Med. Insights Psych."},{"issue":"1","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archpsyc.63.1.102","article-title":"A randomized controlled trial of interim methadone maintenance","volume":"63","author":"Schwartz RP","year":"2006","unstructured":"Schwartz RP, Highfield DA, Jaffe JH A randomized controlled trial of interim methadone maintenance. Arch. Gen. Psychiatry 63(1), 102\u2013109 (2006).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"e_1_3_8_20_2","first-page":"5","article-title":"Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients","volume":"10","author":"Kamien JB","year":"2008","unstructured":"Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict. Relat. Clin. Probl. 10(4), 5\u201318 (2008).","journal-title":"Heroin Addict. Relat. Clin. Probl."},{"issue":"10","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone","volume":"66","author":"Hulse GK","year":"2009","unstructured":"Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch. Gen. Psychiatry 66(10), 1108\u20131115 (2009).","journal-title":"Arch. Gen. Psychiatry"},{"key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"102311","DOI":"10.1016\/j.eclinm.2023.102311","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden J","year":"2023","unstructured":"Marsden J, Kelleher M, Gilvarry E Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. EClinicalMedicine 66, 102311 (2023).","journal-title":"EClinicalMedicine"},{"issue":"2","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/10398562241295872","article-title":"Effectiveness of long-acting buprenorphine - a systematic review","volume":"33","author":"McMaster J","year":"2025","unstructured":"McMaster J, Abeysundera H. Effectiveness of long-acting buprenorphine - a systematic review. Australas. Psychiatry 33(2), 235\u2013248 (2025).","journal-title":"Australas. Psychiatry"},{"key":"e_1_3_8_24_2","unstructured":"US Food & Drug Administration (FDA). Framework for FDA's real-world evidence program. (2018). (Accessed: 15 May 2025). Available from: https:\/\/www.fda.gov\/media\/120060\/download"},{"key":"e_1_3_8_25_2","unstructured":"European Medicines Agency (EMA). Guideline on registry-based studies (2021). (Accessed: 15 May 2025). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-registry-based-studies_en.pdf"},{"issue":"4","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies","volume":"20","author":"Makady A","year":"2017","unstructured":"Makady A, Ham RT, de Boer A, Hillege H, Klungel O, Goettsch W. GetReal Workpackage 1. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health 20(4), 520\u2013532 (2017).","journal-title":"Value Health"},{"key":"e_1_3_8_27_2","unstructured":"CG HTA. Guidance on the validity of clinical studies for joint clinical assessments (2024). (Accessed: 10 February 2025). Available from: https:\/\/health.ec.europa.eu\/document\/download\/9f9dbfe4-078b-4959-9a07-df9167258772_en?filename=hta_clinical-studies-validity_guidance_en.pdf"},{"key":"e_1_3_8_28_2","first-page":"736","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2022","unstructured":"Higgins JPT, Thomas J, Chandler J Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. 736, John Wiley & Sons, NJ, USA (2022).","edition":"2"},{"issue":"11","key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton B","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777\u2013784 (2015).","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela L","year":"2016","unstructured":"Zorzela L, Loke YK, Ioannidis JP PRISMA harms checklist: improving harms reporting in systematic reviews. Brit. Med. J. 352, i157 (2016).","journal-title":"Brit. Med. J."},{"issue":"3","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"e0266142","DOI":"10.1371\/journal.pone.0266142","article-title":"Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials","volume":"17","author":"Lim J","year":"2022","unstructured":"Lim J, Farhat I, Douros A, Panagiotoglou D. Relative effectiveness of medications for opioid-related disorders: a systematic review and network meta-analysis of randomized controlled trials. PLoS ONE 17(3), e0266142 (2022).","journal-title":"PLoS ONE"},{"issue":"6","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt L","year":"2023","unstructured":"Degenhardt L, Clark B, Macpherson G Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psych. 10(6), 386\u2013402 (2023).","journal-title":"Lancet Psych."},{"key":"e_1_3_8_33_2","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias S","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. National Institute for Health and Care Excellence, UK (NICE) (2014)."},{"key":"e_1_3_8_34_2","unstructured":"NICE Decision Support Unit. Evidence Synthesis TSD series (2012). (Accessed: 1 March 2024). Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/evidence-synthesis"},{"key":"e_1_3_8_35_2","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias S","year":"2011","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. National Institute for Health and Care Excellence (NICE), UK (2011)."},{"key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: a package for running WinBUGS from R","volume":"12","author":"Sturtz S","year":"2005","unstructured":"Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J. Stat. Software 12, 1\u201316 (2005).","journal-title":"J. Stat. Software"},{"issue":"17","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels MJ","year":"1997","unstructured":"Daniels MJ, Hughes MD. Meta-analysis for the evaluation of potential surrogate markers. Stat. Med. 16(17), 1965\u20131982 (1997).","journal-title":"Stat. Med."},{"issue":"1","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12874-018-0509-7","article-title":"The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma","volume":"18","author":"Schmitz S","year":"2018","unstructured":"Schmitz S, Maguire \u00c1, Morris J The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Med. Res. Methodol. 18(1), 66 (2018).","journal-title":"BMC Med. Res. Methodol."},{"key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC RoB 2: a revised tool for assessing risk of bias in randomised trials. Brit Med. J. 366, l4898 (2019).","journal-title":"Brit Med. J."},{"key":"e_1_3_8_40_2","unstructured":"Wells GA Shea B O'Connell D The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Accessed: 1 March 2024). Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/0272989X18759488","article-title":"Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analyses","volume":"38","author":"Ren S","year":"2018","unstructured":"Ren S, Oakley JE, Stevens JW. Incorporating genuine prior information about between-study heterogeneity in random effects pairwise and network meta-analyses. Med. Decis. Making 38(4), 531\u2013542 (2018).","journal-title":"Med. Decis. Making"},{"key":"e_1_3_8_42_2","unstructured":"Lee K. Treatment retention with monthly buprenorphine extended release injection: results from a Canadian Rapid Access Addiction Medicine Clinic: 21 Month Data (2025). (Accessed: 10 March 2025). Available from: https:\/\/www.cpmdependance.ca\/documents\/80779\/0\/Ken+Lee+Poster+48+x+36+Version+2+Sept+8+2021+%281%29.pdf\/a0544658-f552-4d93-88d7-cddafe94c27c"},{"key":"e_1_3_8_43_2","volume-title":"European Congress on Heroin Addiction & Related Clinical Problems","author":"Partanen M","year":"2022","unstructured":"Partanen M, Saarenp\u00e4\u00e4 T, Prami T, Iso-Mustaj\u00e4rvi I, Ryder B, Simojoki K. Early experience of buprenorphine long-acting injection in Finland: a retrospective cohort study. Poster presented at: European Congress on Heroin Addiction & Related Clinical Problems, Pisa, Italy, 20\u201322 May 2022."},{"key":"e_1_3_8_44_2","volume-title":"International Society of Addiction Medicine (ISAM) Annual Conference","author":"Partanen M","year":"2025","unstructured":"Partanen M, Saarenp\u00e4\u00e4 T, Prami T Early experiences of buprenorphine long-acting injection in Finland: a retrospective cohort study. Poster presented at: International Society of Addiction Medicine (ISAM) Annual Conference, Hamburg, Germany, 26\u201328 May 2025."},{"key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"103492","DOI":"10.1016\/j.drugpo.2021.103492","article-title":"Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence","volume":"100","author":"Farrell M","year":"2022","unstructured":"Farrell M, Shahbazi J, Byrne M Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. Int. J. Drug Policy 100, 103492 (2022).","journal-title":"Int. J. Drug Policy"},{"key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"104390","DOI":"10.1016\/j.drugpo.2024.104390","article-title":"96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: extended follow-up after a single-arm trial","volume":"127","author":"Farrell M","year":"2024","unstructured":"Farrell M, Shahbazi J, Chambers M 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: extended follow-up after a single-arm trial. Int. J. Drug Policy 127, 104390 (2024).","journal-title":"Int. J. Drug Policy"},{"key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"1236462","DOI":"10.3389\/fmed.2023.1236462","article-title":"Real-world evidence for regulatory decision-making: updated guidance from around the world","volume":"10","author":"Burns L","year":"2023","unstructured":"Burns L, Le Roux N, Kalesnik-Orszulak R Real-world evidence for regulatory decision-making: updated guidance from around the world. Front. Med. 10, 1236462 (2023).","journal-title":"Front. Med."},{"key":"e_1_3_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.01.010"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:15:48Z","timestamp":1770286548000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.57264\/cer-2025-0171"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0171","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"e250171"}}